Roche Group (Half-Year Report, 2010)
Notes to the Roche Group Interim Consolidated Financial Statements [extract]
Note 10. Intangible assets [extract]
Impairment of intangible assets [extract]
In the Pharmaceuticals operating segment a net impairment charge of 102 million Swiss francs was recorded. An impairment charge of 71 million Swiss francs was recorded, which relates to a decision to stop development of one compound with an alliance partner. The assets concerned, which were not yet being amortised, were fully written down by these charges. A further charge of 47 million Swiss francs was recorded, resulting from a portfolio prioritisation decision on a project acquired as part of a previous business combination. The asset concerned, which was not yet being amortised, was written down to its recoverable value of 95 million Swiss francs. A reversal of previously recorded impairment loss of 16 million Swiss francs was recorded, which follows from the latest clinical data assessment of the project concerned.